139356-32-4

Usage

Uses

Used in Pharmaceutical Industry:
(1α,3R,4α,5R)-3,5-Bis[[(1,1-diMethylethyl)diMethylsilyl]oxy]-1-hydroxy-4-(1H-iMidazol-1-ylthioxoMethoxy)-cyclohexanecarboxylic Acid Methyl Ester is used as an intermediate in the synthesis of Vitamin D compounds for the pharmaceutical industry. Its unique structure and functional groups make it a valuable building block for the development of new drugs and therapeutic agents.
Used in Chemical Research:
(1α,3R,4α,5R)-3,5-Bis[[(1,1-diMethylethyl)diMethylsilyl]oxy]-1-hydroxy-4-(1H-iMidazol-1-ylthioxoMethoxy)-cyclohexanecarboxylic Acid Methyl Ester can also be used as a research tool in the field of organic chemistry, particularly in the study of cyclohexane derivatives, silyl ethers, and imidazole-containing compounds. Its synthesis and reactivity can provide insights into the development of new synthetic methods and the exploration of novel chemical reactions.
Used in Material Science:
The unique properties of (1α,3R,4α,5R)-3,5-Bis[[(1,1-diMethylethyl)diMethylsilyl]oxy]-1-hydroxy-4-(1H-iMidazol-1-ylthioxoMethoxy)-cyclohexanecarboxylic Acid Methyl Ester may also find applications in material science, where it could be used to develop new materials with specific properties, such as improved stability, reactivity, or biocompatibility.

Upstream product

• 135711-62-5 methyl quinicate 
• 6160-65-2 1,1'-Thiocarbonyldiimidazole 
• 77-95-2 D-(-)-quinic acid 
• 191916-39-9 methyl (-)-quinate 

Downstream Products

• 1443929-45-0 C₂₅H₄₇NO₂Si₂ 
• 139356-40-4 (1R,7aR)-4-[2-[(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-cyclohexylidene]-eth-(E)-ylidene]-1-((R)-1,5-dimethyl-5-trimethylsilanyloxy-hexyl)-7a-methyl-octahydro-indene 
• 139356-39-1 (1R,3R)-1,3-bis((tert-butyldimethyl)silanyloxy)-5-[2-(diphenylphosphinoyl)-ethylidene]cyclohexane 
• 139356-36-8 [(3R,5R)-3,5-bis-(tert-butyldimethylsilyloxy)cyclohexylidene]acetic acid ethyl ester 
• 139356-38-0 ((1R,3R)-5-(2-chloroethylidene)cyclohexane-1,3-diyl)bis(oxy)bis(tert-butyldimethylsilane) 
• 139356-37-9 [(3R,5R)-3,5-bis-(tert-butyldimethylsilanyloxy)cyclohexylidene]-ethanol 
• 139356-35-7 3,5-di-(tert-butyl-dimethylsilyloxy)-(3S,5S)-cyclohexan-1-one 
• 139356-34-6 (3S,5S)-3,5-bis[tert-butyl(dimethyl)silyloxy]-1-(hydroxylmethyl)cyclohexanol 
• 301153-96-8 (3R,3aR,7aR)-7-[(3S,5S)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-cyclohex-1-enylethynyl]-3-((R)-1,5-dimethyl-5-trimethylsilanyloxy-hexyl)-3a-methyl-2,3,3a,4,5,7a-hexahydro-1H-indene 
• 301153-97-9 (3R,3aR,7aR)-7-[(3R,5S)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-cyclohex-1-enylethynyl]-3-((R)-1,5-dimethyl-5-trimethylsilanyloxy-hexyl)-3a-methyl-2,3,3a,4,5,7a-hexahydro-1H-indene 
• 301153-98-0 1α,25-dihydroxy-6,7-dehydro-3-epi-19-nor-previtamin D₃ 
• 301153-99-1 1β,25-dihydroxy-6,7-dehydro-3-epi-19-nor-previtamin D₃ 
• 301153-90-2 methyl (3R,5S)-3,5-di[(p-nitrophenylcarbonyl)oxy]-cyclohex-1-enecarboxylate 
• 301153-84-4 methyl (3S,5S)-3,5-di[(p-nitrophenylcarbonyl)oxy]-cyclohex-1-enecarboxylate 

Relevant academic research and scientific papers

Synthesis of imidazoylthiocarbonyl intermediates for the radical deoxygenation of hindered secondary alcohols

A practical and efficient synthesis of imidazoylthiocarbonyl derivatives of highly hindered alcohols was achieved using 1,1′-thiocarbonyldiimidazole in very concentrated mixtures of reagents. More diluted conditions give longer reaction times and the reco

1-DEOXY ANALOGS OF VITAMIN D-RELATED COMPOUNDS

This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferativ

HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES

Hybrid molecules comprising a vitamin D receptor agonist moiety and an HDAC inhibitor moiety are described herein The HDAC inhibitor moiety can be modelled after an HDAC inhibitor selected from the group consisting of tπchostatm A, sodium butyrate, valpro

Efficient and convergent coupling route for the short-step synthesis of enantiopure 2α- and 2β-alkylated 1α,25-dihydroxy-19-norvitamin D3 analogues

Novel efficient synthesis of several enantio-pure 2-alkylated 1α,25-dihydroxy-19-norvitamin D3 analogues through radical introduction of 2-alkyl chain and C5-C6 position coupling using Julia-type olefination as key steps w

6-s-cis locked analogues of the steroid hormone 1α,25-dihydroxyvitamin D3. Synthesis of novel A-ring stereoisomeric 1,25-dihydroxy-3-epi-19-nor-previtamin D3 derivatives

Efficient syntheses of A-ring synthons 24 and 32 are described from hydroxy ester 16, which is easily available on a preparative scale from (-)-quinic acid. Key features of the syntheses were (a) the ability to selectively perform desilylations in the presence of p-nitrobenzoate esters and (b) the excellent yield and complete stereospecificity with which the configuration of alcohols 16, 18, and 26 could be inverted under Mitsunobu conditions. Thus, A-ring synthons 24 and 32 were both prepared in 35-38% yield (eight steps) from the common precursor 16. The coupling of A-ring synthons 24 and 32 with the appropriate CD-ring/side chain fragment 7 provides access to novel 6-s-cis locked analogues of steroid hormone 1α,25-dihydroxyvitamin D3: 1α,25-dihydroxy-3-epi-19-nor-previtamin D3 (37) and 1β,25-dihydroxy-3-epi-19-nor-previtamin D3 (38), which are unable to undergo rearrangement to the respective vitamin D form by virtue of the absence of the C-19 methyl group. Compounds 37 and 38 can be used as tools for studying the genomic and nongenomic mechanisms of action of the previtamin form of the hormone 1α,25-dihydroxyvitamin D3.

Novel synthesis of 19-nor-vitamin D compounds

1α,25-Dihydroxy-19-nor-vitamin D3 was prepared efficiently in a convergent synthesis starting with (-)-quinic acid and a ketone of the Windaus-Grundmann type.